Chinese Medicine for Idiopathic Parkinson's Disease: A Meta Analysis of Randomized Controlled Trials

Objective

To evaluate the efficacy of Chinese medicine (CM) adjunct to conventional medications for idiopathic Parkinson’s disease (PD).

Methods

Electronic English and Chinese databases including PubMed, Cochrane Library, Web of Science, Chinese Medical Current Contents, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Med Database, and Traditional Chinese Medical Database System were used for key words searching in a highly sensitive search strategy. The extracted data was analyzed by the Review Manager 5.0.

Results

Twelve trials involving 869 participants were included in the meta-analysis. Unified PD Rating Scale (UPDRS) I, II, III, IV scores and UPDRS V–IV total scores were used to be the primary outcomes, Parkinson Disease Question-39 (PDQ-39) and Scores of Chinese Medical Symptoms were the secondary outcomes. CM adjunct therapy had greater improvement in UPDRS I [2 trials; standardized mean difference (SMD)–0.40, 95% confidence interval (CI)–0.71 to–0.09; Z=2.49 (P=0.01)], II [5 trials; SMD–0.47, 95% CI–0.69 to–0.25; Z=4.20 (P<0.01)], III [5 trials; SMD-0.35, 95% CI–0.57 to–0.13; Z=3.16 (P=0.002)], IV scores [3 trials; SMD-0.32, 95% CI–0.60 to–0.03; Z=2.17 (P=0.03)], UPDRS I–IV total scores [7 trials; SMD-0.36, 95%CI–0.53 to–0.20; Z=4.24 (P<0.05)]. PDQ-39 and Chinese medical symptoms compared to the conventional medication only.

Conclusion

CM adjunct therapy has potential therapeutic benefits by decreasing UPDRS scores and reducing adverse effect.